TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Clinical trial NCT06538012 · RECRUITING

Trial details

NCT number: NCT06538012
Sponsor: Essen Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lung Cancer Lung Cancer Metastatic Lung Cancer, Non-small Cell Lung Cancer Recurrent

Start date: 2024-08-20
Primary completion: 2026-09-10
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.